AML patients non-responders to the treatment with azacitidine and nivolumab, an anti-PD-1, show the upregulation of CTLA-4 on CD4+ T cells, supporting the rationale to add ipilimumab, an anti-CTLA-4, to the regimen [190]. The gene discussed is CD4; the disease is acute myeloid leukemia.